Qwixel Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Qwixel Therapeutics General Information

Description

Developer of drugs based in Los Angeles, USA. The company developed immune cytokines drugs that combine antibodies with proteins that stimulate immune responses, enabling patients to improve their immunity.

Contact Information

Website
www.qwixelt.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 258 Denslow Avenue
  • Los Angeles, CA 90049-3223
  • United States
Primary Industry
Drug Discovery
Corporate Office
  • 258 Denslow Avenue
  • Los Angeles, CA 90049-3223
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Qwixel Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 01-Jan-2021 Completed Generating Revenue
3. Grant 05-Jun-2019 Completed Generating Revenue
2. Early Stage VC 01-Jan-2019 $10M $10M Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Qwixel Therapeutics’s complete valuation and funding history, request access »

Qwixel Therapeutics Patents

Qwixel Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2025084914-A Fusion protein composition comprising targeted masked type i interferons (ifna and ifnb) and antibody against tumor antigen, for use in treatment of cancer Pending 15-Apr-2019
US-11136353-B2 Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof Active 15-Apr-2019
US-11795198-B2 Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof Active 15-Apr-2019
US-20200331966-A1 Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof Active 15-Apr-2019
US-20220056076-A1 Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof Active 15-Apr-2019 A61K38/10
To view Qwixel Therapeutics’s complete patent history, request access »

Qwixel Therapeutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Magnify Accelerator/Incubator
National Institutes of Health Government
To view Qwixel Therapeutics’s complete investors history, request access »

Qwixel Therapeutics FAQs

  • When was Qwixel Therapeutics founded?

    Qwixel Therapeutics was founded in 2016.

  • Where is Qwixel Therapeutics headquartered?

    Qwixel Therapeutics is headquartered in Los Angeles, CA.

  • What industry is Qwixel Therapeutics in?

    Qwixel Therapeutics’s primary industry is Drug Discovery.

  • Is Qwixel Therapeutics a private or public company?

    Qwixel Therapeutics is a Private company.

  • What is Qwixel Therapeutics’s current revenue?

    The current revenue for Qwixel Therapeutics is .

  • How much funding has Qwixel Therapeutics raised over time?

    Qwixel Therapeutics has raised $10M.

  • Who are Qwixel Therapeutics’s investors?

    Magnify and National Institutes of Health have invested in Qwixel Therapeutics.

  • When was Qwixel Therapeutics acquired?

    Qwixel Therapeutics was acquired on 01-Jan-2021.

  • Who acquired Qwixel Therapeutics?

    Qwixel Therapeutics was acquired by Nammi Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process